The FREEDOM 1 Clinical Study for kidney transplant recipients is to learn more about the safety and effectiveness of FCR001 treatment to prevent rejection of living donor kidney transplants without the need of life-long anti-rejection drugs.
Find out more...
Find out if you are a good candidate and get your questions answered by Dr. Marsh, chief of Scripps Organ Transplantation Service in the division of organ transplantation, surgical program director of the Scripps Center for Organ Transplantation and currently chief of staff for Scripps Green Hospital.
October 18, 2021 — 11:00 AM Pacific Time (US and Canada)
FAIR Foundation Mission
FAIR promotes policies and activities that increase the availability, access and health equity of solid organ transplantation in the United States through patient education, support and advocacy.
Did you know?
1 in 10 people will get some form of liver disease in their lifetime and 1 in 7 people will suffer from chronic kidney disease in this country. And someday, they may need a transplant, but there is an organ shortage in this country. The wait for a kidney can be 7 to 10 years on the east and west coasts.
The goal is to prevent liver and kidney disease. But, if someone needs a life saving transplant — we want to make sure everyone who needs a transplant gets one regardless of race, income level or where they live. Donate to the effort!
FAIR supports the Acuity Circle Model for the allocation of livers to candidates within 150, 250, or 500 nautical miles (nm) of donor hospitals before offering them nationally to allow for efficient placement of donor organs and to avoid organ wastage.
Improving Medicare Patients’ Access to Kidney Transplantation Resolution as introduced by The American Society of Transplant Surgeons to AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES
Clinical Trial for
If you plan to receive a kidney transplant from a living donor, you and your living donor may be eligible to participate in a research study called the FREEDOM-1 Study. The FREEDOM-1 Study is evaluating an investigational treatment that could potentially eliminate the need for anti-rejection drugs among living donor kidney transplant recipients. Get your questions answered by transplant surgeon, Dr. Christopher Marsh, MD, FACS, chief of the Scripps Organ Transplantation Service in the division of organ transplantation and surgical program director of the Scripps Center for Organ Transplantation. Register here: https://mailchi.mp/e3a3587c8c67/freedom1https://mailchi.mp/e3a3587c8c67/freedom1
Physicians specializing in the treatment of kidney/liver disease, transplantation surgeons, dieticians and social service experts volunteer their time to help you understand and manage your disease in an informal, non clinical settings.